Buffalo Urologist Dr. Kent Chevli Named UroLift Center of Excellence for Treatment of Enlarged Prostate Symptoms

News Image

“I am pleased to offer my patients a breakthrough treatment for symptoms associated with this common condition that can cause bothersome symptoms that interfere with everyday living

Western New York Urology (WNYU), in conjunction with the Buffalo Ambulatory Surgery Center, is proud to announce Dr. Kent Chevli has been named a UroLift Center of Excellence. The honor recognizes Dr. Chevli’s deep experience with the Prostatic Urethral Lift (PUL) procedure, using the UroLift® System, for the treatment of symptoms associated with Benign Prostatic Hyperplasia or BPH. Dr. Chevli is the second urologist within WNYU to earn this distinction.

“I am pleased to offer my patients a breakthrough treatment for symptoms associated with this common condition that can cause bothersome symptoms that interfere with everyday living,” said Dr. Chevli. “Through my partnership with the Buffalo Ambulatory Surgery Center, I am able to make this minimally invasive treatment, that takes less than an hour to perform, widely available to men in the Buffalo area,” he added. “I am proud to be a national leader in treating patients with this medical technique that is durable and effective.”

Nearly 40 million men in the United States are affected by BPH. This condition occurs as the prostate gland that surrounds the male urethra becomes enlarged, exerting pressure on the urethra and restricting or blocking urine flow. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medications can be helpful in relieving symptoms for some men, but patients must continue taking them long-term to maintain the effects. Some patients may suffer side effects including dizziness, headaches, or sexual dysfunction. And some may not get adequate relief of their symptoms. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract Interventional Urology’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About Western New York Urology
Founded in 1996, Western New York Urology has nine locations across the region, including sites in Cheektowaga, Cambria, Orchard Park, Jamestown, Dunkirk, Corfu, Hamburg, Derby and Springville. The practice has affiliation agreements with 23 hospitals and outpatient sites in the region and serves as a resident training site for the University at Buffalo School of Medicine & Biomedical Sciences.

Western New York Urology Associates, LLC.

Media Contact:
Amy Cramer
M: 650-391-3714

Powered by WPeMatico